Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial

被引:4
|
作者
Howard, Robert [1 ]
Cort, Elizabeth [1 ]
Rawlinson, Charlotte [1 ]
Wiegand, Martin [2 ]
Downey, Anne [2 ]
Lawrence, Vanessa [3 ]
Banerjee, Sube [4 ]
Bentham, Peter [5 ]
Fox, Chris [6 ]
Harwood, Rowan [7 ]
Hunter, Rachel [2 ]
Livingston, Gill [1 ]
Moniz-Cook, Esme [8 ]
Panca, Monica [2 ]
Raczek, Malgorzata [9 ]
Ivenso, Chineze [10 ]
Russell, Gregor [11 ]
Thomas, Alan [12 ]
Wilkinson, Philip [13 ]
Freemantle, Nicholas [14 ]
Gould, Rebecca [1 ]
机构
[1] UCL, Div Psychiat, London, England
[2] UCL, Priment Clin Trials Unit, London, England
[3] Kings Coll London, David Goldberg Ctr H1 01, London, England
[4] Univ Plymouth, Plymouth, Devon, England
[5] Birmingham & Solihull NHS Trust, Birmingham, England
[6] Univ East Anglia, Norwich, Norfolk, England
[7] Univ Nottingham, Queens Med Ctr, Nottingham, England
[8] Univ Hull, Kingston Upon Hull, England
[9] Brighton & Sussex Sch Med, Brighton, E Sussex, England
[10] Aneurin Bevan NHS Trust, St Cadocs Hosp, Newport, Wales
[11] Bradford Dist Care Fdn Trust, Bradford, England
[12] Univ Newcastle, Campus Ageing & Vital, Newcastle Upon Tyne, England
[13] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England
[14] UCL, Comprehens Clin Trials Unit, London, England
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trial; depression; mood; problem adaptation therapy; psychological; psychotherapy; MINI-MENTAL-STATE; ANXIETY; PEOPLE; SCALE;
D O I
10.1002/alz.13766
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION: Trials of effectiveness of treatment options for depression in dementia are an important priority. METHODS: Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in mild/moderate dementia caused by Alzheimer's disease. RESULTS: Three hundred thirty-six participants with mild or moderate dementia, >7 on Cornell Scale for Depression in Dementia (CSDD), randomized to adapted PATH or treatment as usual. Mean age 77.0 years, 39.0% males, mean Mini-Mental State Examination 21.6, mean CSDD 12.9. For primary outcome (CSDD at 6 months), no statistically significant benefit with adapted PATH on the CSDD (6 months: -0.58; 95% CI -1.71 to 0.54). The CSDD at 3 months showed a small benefit with adapted PATH (-1.38; 95% CI -2.54 to -0.21) as did the EQ-5D (-4.97; 95% CI -9.46 to -0.48). DISCUSSION: An eight-session course of adapted PATH plus two booster sessions administered within NHS dementia services was not effective treatment for depression in people with mild and moderate dementia. Future studies should examine the effect of more intensive and longer-term therapy.
引用
收藏
页码:2990 / 2999
页数:10
相关论文
共 50 条
  • [41] Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Bruno Dubois
    Jesús López-Arrieta
    Stanley Lipschitz
    Triantafyllos Doskas
    Luiza Spiru
    Svitlana Moroz
    Olena Venger
    Patrick Vermersch
    Alain Moussy
    Colin D. Mansfield
    Olivier Hermine
    Magda Tsolaki
    Alzheimer's Research & Therapy, 15
  • [42] Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease:: a double blind, randomized and placebo-controlled trial
    Akhondzadeh, S
    Noroozian, M
    Mohammadi, M
    Ohadinia, S
    Jamshidi, AH
    Khani, M
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (01) : 53 - 59
  • [43] Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
    Wilcock, GK
    Lilienfeld, S
    Gaens, E
    BRITISH MEDICAL JOURNAL, 2000, 321 (7274): : 1445 - 1449
  • [44] A Multicenter, Randomized, Controlled Trial of Electroacupuncture for Perimenopause Women with Mild-Moderate Depression
    Li, Sheng
    Li, Zhao-Feng
    Wu, Qian
    Guo, Xiao-Chuan
    Xu, Zhen-Hua
    Li, Xiao-Bin
    Chen, Rong
    Zhou, Dao-you
    Wang, Cong
    Duan, Quan
    Sun, Jian
    Luo, Ding
    Li, Min-Ying
    Wang, Jun-Ling
    Xie, Hui
    Xuan, Li-Hua
    Su, Sheng-Yong
    Huang, Dong-Mian
    Liu, Zhi-Shun
    Fu, Wen-Bin
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [45] Longitudinal cognitive training program in people with mild Alzheimer's disease: A Randomized Controlled Trial
    Poptsi, Eleni
    Kounti, Fotini
    Samakouri, Maria
    Vorvolakos, Theofanis
    Tsolaki, Magda
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2017, 20 (02) : 233 - 243
  • [46] A randomized controlled trial of prednisone in Alzheimer's disease
    Aisen, PS
    Davis, KL
    Berg, JD
    Schafer, K
    Campbell, K
    Thomas, RG
    Weiner, MF
    Farlow, MR
    Sano, M
    Grundman, M
    Thal, LJ
    NEUROLOGY, 2000, 54 (03) : 588 - 593
  • [47] The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
    Li, Mo
    Lyu, Ji-hui
    Zhang, Yi
    Gao, Mao-long
    Li, Wen-jie
    Ma, Xin
    MEDICINE, 2017, 96 (51)
  • [48] The Feasibility of a Mindfulness Intervention for Depression in People with Mild Dementia: A Pilot Randomized Controlled Trial
    Noone, Deirdre
    Payne, Jacob
    Stott, Josh
    Aguirre, Elisa
    Patel-Palfreman, Ms Mina
    Stoner, Charlotte
    Hanrachtaigh, Eanna O.
    Spector, Aimee
    CLINICAL GERONTOLOGIST, 2023, 46 (03) : 346 - 358
  • [49] A randomized sham-controlled trial of transcranial and intranasal photobiomodulation in Japanese patients with mild cognitive impairment and mild dementia due to Alzheimer's disease: a protocol
    Yokoi, Yuma
    Inagawa, Takuma
    Yamada, Yuji
    Matsui, Makoto
    Tomizawa, Asumi
    Noda, Takamasa
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [50] Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial
    Rash, Brian G.
    Ramdas, Kevin N.
    Agafonova, Nataliya
    Naioti, Eric
    McClain-Moss, Lisa
    Zainul, Zarin
    Varnado, Brittany
    Peterson, Kevin
    Brown, Michael
    Leal, Thiago
    Kopcho, Steven
    Carballosa, Raul
    Patel, Paayal
    Brody, Mark
    Herskowitz, Brad
    Fuquay, Ana
    Rodriguez, Savannah
    Jacobson, Alan F.
    Leon, Ramon
    Pfeffer, Michael
    Schwartzbard, Julie B.
    Botbyl, Jeffrey
    Oliva Jr, Anthony A.
    Hare, Joshua M.
    NATURE MEDICINE, 2025, : 1257 - 1266